Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 US FDA determines Baska facility inspection classification as OAI
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The US FDA has classified its inspection of Sun Pharma's Baska manufacturing facility as 'Official Action Indicated' (OAI), which is the most serious inspection outcome. OAI means the regulator found significant regulatory violations and intends to take enforcement action, such as issuing a warning letter or an import alert. Sun Pharma has stated it is evaluating the next steps and will respond to the FDA within the stipulated timeframe. The Baska facility contributes to Sun Pharma's US generic business, and any restrictions could affect supply and revenue from that market.
OAI classification is negative for Sun Pharma — it could lead to import alerts, warning letters, or delays in new approvals from this site, potentially impacting US revenues and margins. Watch for further FDA correspondence and company updates on remediation plans.